COLUMBIA, Md.--(BUSINESS WIRE)--Welldoc®, a leading digital health company specializing in AI-driven cardiometabolic health, today announced significant advancements in its AI research strategy, focused on responsible AI integration in healthcare. The company presented a series of clinical publications on the application of its novel generative AI model designed to improve health outcomes through predictive analytics at leading industry conferences throughout October, including FNCE, DTM and INFORMS.

马里兰州哥伦比亚市——（商业新闻短讯）——专门从事人工智能驱动的心脏代谢健康的领先数字健康公司Welldoc®今天宣布，其人工智能研究战略取得了重大进展，重点是将负责任的人工智能整合到医疗保健中。该公司在整个10月的主要行业会议（包括FNCE，DTM和INFORMS）上发布了一系列关于其新型生成人工智能模型应用的临床出版物，旨在通过预测分析改善健康结果。

This research expands upon Welldoc's impressive portfolio of 37 AI-focused publications, solidifying the Company’s leadership in developing responsible and judicious AI solutions for healthcare..

。。

Welldoc's evolving strategy prioritizes investment in AI-driven clinical research and partnerships with leading public, academic and private partners. This collaborative approach fosters diversity and breadth in their datasets, enabling more robust predictive analytics to support deeply personalized health progress and outcomes.

Welldoc不断发展的战略优先投资于人工智能驱动的临床研究，并与领先的公共、学术和私人合作伙伴建立伙伴关系。这种协作方法促进了他们数据集的多样性和广度，使更强大的预测分析能够支持深度个性化的健康进展和结果。

Additionally, Welldoc's expertise in navigating regulatory oversight of AI-enabled solutions positions the Company to bring these offerings to individuals living with complex cardiometabolic conditions like diabetes..

此外，Welldoc在人工智能解决方案监管方面的专业知识使公司能够将这些产品带给患有糖尿病等复杂心脏代谢疾病的个人。。

'We believe that when AI is properly tested and integrated into care models, it has the potential to transform the continuum of care, personalize the cardiometabolic health journey and help providers optimize clinical decisions,' said Anand Iyer, PhD, MBA, Chief AI Officer of Welldoc. 'Welldoc's AI is illuminating novel insights across risk and clinical outcomes by harnessing the power of advancements in real-time sensor data and an individual's unique health journey.'.

Welldoc首席人工智能官、MBA博士阿南德·伊耶（Anand Iyer）说：“我们相信，当人工智能经过适当测试并整合到护理模式中时，它有可能改变护理的连续性，个性化心脏代谢健康旅程，并帮助提供者优化临床决策。”Welldoc的人工智能通过利用实时传感器数据的进步和个人独特的健康旅程，为风险和临床结果提供了新的见解。”。

Welldoc's AI research has centered around predicting outcomes, such as weight, and leveraging the power of real-time sensors, like continuous glucose monitors (CGM), to provide meaningful insights for complex condition support. Recent research from Welldoc, presented at FNCE, used AI-modeling and Shapley analysis to predict at least 3% weight loss with 93% accuracy, as well as the effect of variables like nutrients and time-based correlations.

Welldoc的人工智能研究集中在预测体重等结果，并利用实时传感器（如连续血糖监测仪（CGM））的功能，为复杂的病情支持提供有意义的见解。在FNCE上发表的Welldoc最近的研究使用AI建模和Shapley分析来预测至少3%的体重减轻，准确率为93%，以及营养素和基于时间的相关性等变量的影响。

Another publication, presented earlier this fall at MLHC, revealed a new generative large sensor model (LSM) capable of predicting future glucose levels 50% more accurately than current state-of-the-art approaches. As real-time sensor innovations become more accessible and affordable, the need for digital health solutions that translate this data into personalized, predictive insights will be crucial in order to guide individuals toward better health..

今年秋天早些时候在MLHC上发表的另一篇出版物揭示了一种新的生成性大型传感器模型（LSM），该模型能够比目前最先进的方法更准确地预测未来的血糖水平50%。随着实时传感器创新变得更加容易获得和负担得起，为了引导个人走向更好的健康，将这些数据转化为个性化的预测性见解的数字健康解决方案的需求将至关重要。。

'Emerging metrics like time in tight range (TITR) and glucose risk index (GRI) are essential for understanding an individual's glucose control, but what's often missing is the personalized guidance needed to achieve optimal levels for these metrics,' said David Klonoff, MD, CEO of Diabetes Technology Society.

糖尿病技术协会首席执行官大卫·克洛诺夫（DavidKlonoff）医学博士说：“对于了解个人的血糖控制情况，诸如严格控制时间（TITR）和血糖风险指数（GRI）等新兴指标至关重要，但通常缺少的是实现这些指标最佳水平所需的个性化指导。”。

'Models like Welldoc's, that use AI, are enabling the delivery of invaluable insights and coaching to guide individuals’ actions around activity, nutrition and medication regimens so they can optimize these health measures.”.

“像Welldoc这样使用人工智能的模型，能够提供宝贵的见解和指导，以指导个人在活动、营养和药物治疗方案方面的行动，从而优化这些健康措施。”。

Welldoc is being recognized for its leadership in both AI and digital health, with the Company being selected as a winner of the 2024 Healthcare AI Impact Awards, MedTech Breakthrough Awards, Innovation Awards by Business Intelligence Group and Top 100 Healthcare Technology Companies by the Healthcare Technology Report.

Welldoc因其在人工智能和数字健康领域的领先地位而受到认可，该公司被评为2024年医疗保健人工智能影响奖、MedTech突破奖、商业智能集团创新奖和医疗保健技术报告100强医疗保健技术公司的得主。

Additionally, Anand Iyer was recently named to Constellation Research’s AI 150 list and was invited to speak at their inaugural AI Summit, as well as at leading AI conferences like Frontiers Health in Berlin and Global Digital Health Summit in Mumbai..

此外，阿南德·艾耶（Anand Iyer）最近被提名为星座研究公司（Constellation Research）的AI 150名单，并应邀在其首届AI峰会上发表演讲，以及在柏林前沿健康和孟买全球数字健康峰会等主要AI会议上发表演讲。。

Welldoc will be hosting a webinar on AI in healthcare featuring industry experts, as well as other upcoming educational events. To sign up to receive updates, visit www.welldoc.com/updates

Welldoc将举办一场关于医疗保健中人工智能的网络研讨会，由行业专家参加，以及其他即将举行的教育活动。要注册接收更新，请访问www.welldoc.com/updates

For more information on Welldoc’s latest AI-focused research, visit www.welldoc.com/clinical-research

有关Welldoc最新人工智能研究的更多信息，请访问www.Welldoc.com/clinical-research

About Welldoc

关于Welldoc

Welldoc®, a digital health leader revolutionizing cardiometabolic care, is integrating personalized, real-time and actionable insights into the daily lives of individuals living with cardiometabolic conditions, enabling improved health and outcomes. Welldoc’s comprehensive digital health platform provides AI-powered digital coaching across pre-diabetes, diabetes, hypertension, heart failure and weight and obesity management, with integrated mental wellbeing and sleep support.

Welldoc®是一家革新心脏代谢护理的数字健康领导者，正在将个性化、实时和可行的见解整合到患有心脏代谢疾病的个人的日常生活中，从而改善健康和预后。Welldoc的综合数字健康平台为糖尿病前期、糖尿病、高血压、心力衰竭以及体重和肥胖管理提供人工智能支持的数字指导，并提供综合的心理健康和睡眠支持。

Welldoc’s flagship product, BlueStar®, is an FDA-cleared digital health solution that guides individuals through the complicated journey of living with diabetes by enabling them to self-manage their care while enhancing connections to their healthcare team. These capabilities are now integrated into the Welldoc platform, providing comprehensive and flexible support across conditions.

Welldoc的旗舰产品BlueStar®是FDA批准的数字健康解决方案，通过使个人能够自我管理自己的护理，同时增强与医疗团队的联系，引导个人度过糖尿病的复杂旅程。这些功能现已集成到Welldoc平台中，可在各种条件下提供全面而灵活的支持。

The company partners with health plans, health systems and employers with the goal of extending care, improving health and reducing costs..

该公司与健康计划、健康系统和雇主合作，旨在提供护理、改善健康状况和降低成本。。

Welldoc has achieved 11 510(k) clearances for diabetes functionality within its digital health platform, and an IP portfolio of 48 patents for its advanced AI and first-in-class tech. With over 90 clinical publications, Welldoc has also built an extensive library of clinical research, including many publications focused on the value of combining CGM with AI-powered digital health solutions.

Welldoc在其数字健康平台中获得了11 510（k）项糖尿病功能许可，其先进人工智能和一流技术拥有48项专利的知识产权组合。Welldoc拥有90多篇临床出版物，还建立了广泛的临床研究库，包括许多专注于将CGM与人工智能数字健康解决方案相结合的价值的出版物。

Welldoc is an industry thought leader and has been showcased in prestigious conferences and publications, including South by Southwest, the Wall Street Journal and the Economist. The company has been named the “Best Overall Digital Health Company” by MedTech Breakthrough for the past two years, and was selected as a winner of the 2024 Healthcare AI Impact Awards, Innovation Awards by Business Intelligence Group and Top 100 Healthcare Technology Companies by the Healthcare Technology Report.

Welldoc是一位行业思想领袖，曾在著名的会议和出版物上展示，包括《西南偏南》、《华尔街日报》和《经济学人》。过去两年，该公司被MedTech Breakthrough评为“最佳整体数字健康公司”，并被评为2024年医疗保健AI影响力奖、商业智能集团创新奖和医疗保健技术报告100强医疗保健技术公司的得主。

For more information, visit www.welldoc.com. Follow us on LinkedIn and Twitter..

有关更多信息，请访问www.welldoc.com。在LinkedIn和Twitter上关注我们。。